Journal of Pharmaceutics & Drug Delivery ResearchISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Bassam Damaj Author

bassam@damaj.cn

Subjects of specialization
Apoptosis;

Affiliation
Dr. Bassam Damaj

Biography

Dr. Bassam Damaj was appointed to serve as the President, CEO, and a member of the Board of Directors of  Innovus Pharmaceuticals, Inc. on January 22, 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President & Chief Executive Officer of Apricus Biosciences, Inc., (NASDAQ: APRI) from December 2009 until November 2012.
 

Publications

Rapid Communication Subscription

Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,NDimethylaminopropionate (DDAIP)

Author(s):

Susan R. Meier-Davis, Salma Debar, Richard Martin, Mohamed Hachicha and Bassam Damaj

Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N, NDimethylaminopropionate (DDAIP)

Penetration of drug through the stratum corneum to reach the underlying epidermal and dermal layers is a critical step for effective therapy by the topical route. To enhance permeation, various penetration enhancers have been utilized in combination with active drugs. The novel excipient, dodecyl-2-N,Ndimethylaminopropionate (DDAIP), was utilized to assess the epidermal penetration of tolnaftate. Tolnaftate, an anti-fungal agent, is approved as an ov... view more»

DOI: 10.4172/2325-9604.1000102

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP